Chronic leukaemias: CML versus CLL (and hairy cell leukaemia)
- Look-alikes compared
Chronic leukaemias are often found by chance on a routine blood test. CML and CLL share a name but behave and are treated very differently.
What it is
In the chronic leukaemias the malignant cells still mature, so the blood fills with cells that look nearly normal and the disease moves slowly. Chronic myeloid leukaemia (CML) is a myeloproliferative neoplasm driven by the BCR::ABL1 fusion (the Philadelphia chromosome, t(9;22)). Chronic lymphocytic leukaemia (CLL) is a lymphoma of mature B cells that circulates in the blood. Hairy cell leukaemia is a rarer mature B-cell leukaemia with pancytopenia and a big spleen.
The difference in one line
- CML: any adult age; a very high white count with neutrophils, myelocytes, basophils and eosinophils; a very large spleen; tyrosine kinase inhibitors aimed at BCR::ABL1 have made it a controllable disease for most patients.
- Untreated CML moves from a chronic phase to accelerated phase and blast crisis (acute leukaemia).
- CLL: older adults; a raised count of small mature lymphocytes with smudge cells; markers CD5, CD19, CD20 (weak) and CD23.
- CLL weakens immunity (low antibodies) and causes autoimmune haemolysis and ITP; it can transform into an aggressive lymphoma (Richter transformation).
- Early CLL without symptoms or cytopenias is watched, not treated: treatment starts when the disease causes problems.
- Hairy cell leukaemia: middle-aged men, pancytopenia, monocytopenia, big spleen without big nodes, BRAF V600E, a dry tap on marrow aspiration.
- LGL leukaemia: a slow clone of cytotoxic T cells (or NK cells), median age 55–60; neutropenia and infections dominate, about a third have an autoimmune disease (mostly rheumatoid arthritis), and treatment, when needed, is immunosuppressive.
- Prolymphocytic leukaemia now means T-PLL: an aggressive mature T-cell leukaemia with a very high count, big liver and spleen, and TCL1 and ATM changes. B-PLL was dropped from the 2022 WHO classification and its cases reassigned.
- BPDCN is not chronic: an aggressive blast neoplasm, mostly of older men, that usually starts in the skin and spreads to marrow, blood and nodes; its blasts are CD4+ CD56+ CD123+.
Chronic leukaemias and three rare look-alikes
| Leukaemia | Line | Blood | Spleen and nodes | Marker | Main risks |
|---|---|---|---|---|---|
| CML | Myeloid | Very high white count, all stages of myeloid cells, basophils up | Very large spleen, nodes usually normal | BCR::ABL1, t(9;22) | Blast crisis if uncontrolled |
| CLL | Mature B lymphocytes | High count of small lymphocytes, smudge cells | Nodes enlarged, spleen variable | CD5 + CD23 on B cells (flow cytometry) | Infections, autoimmune cytopenias, Richter transformation |
| Hairy cell leukaemia | Mature B lymphocytes | Pancytopenia, few hairy cells, low monocytes | Very large spleen, nodes usually normal | BRAF V600E; CD11c, CD25, CD103 | Infections from pancytopenia |
| LGL leukaemia | Cytotoxic T cells (most) or NK cells | Excess large granular lymphocytes; neutropenia most often, also anaemia | Spleen enlarged in 20–50%, nodes rarely | Clonal T-cell receptor, CD3+ CD8+ CD57+; STAT3 mutation | Infections from neutropenia; rheumatoid arthritis, pure red cell aplasia |
| T-cell prolymphocytic leukaemia | Mature T cells | Very high count (often over 100 × 10⁹/L), anaemia, low platelets | Big liver and spleen, non-bulky nodes; skin, oedema or effusions in some | TCL1 overexpression, ATM loss | Aggressive: median survival under 3 years even with treatment |
| BPDCN | Plasmacytoid dendritic cell precursors (blasts) | Blasts in the blood in 15–68%; marrow involved in 46–95% | Nodes involved in 24–63%, spleen in about 20% | CD4+ CD56+ CD123+, no T-cell marker (CD3 negative) | Skin lesions in 80–97%; rapidly fatal without intensive therapy |
In clinical practice
- An older person with a lymphocytosis on a routine count and painless nodes most often has CLL.
- Left upper quadrant fullness or early satiety from a huge spleen is a common first complaint in CML.
- Patients with CLL need vaccinations and early treatment of infections because of low antibody levels.
How it is confirmed
- Suspected CML: BCR::ABL1 by PCR (and cytogenetics or FISH); the same PCR measures the response to treatment.
- Suspected CLL: flow cytometry of the blood confirms a clonal B-cell population with the typical markers; a marrow is not needed for diagnosis.
- CLL follow-up: count, immunoglobulins and DAT if anaemia appears; new rapidly growing nodes or B symptoms need a biopsy for Richter transformation.
- Pancytopenia with a big spleen and low monocytes: flow cytometry and marrow biopsy for hairy cell leukaemia.
- Suspected LGL leukaemia: blood flow cytometry (CD3, CD8, CD57, CD16, CD56) and T-cell receptor gene rearrangement for clonality.
- Skin nodules or plaques with blasts in an older man: skin biopsy stained for CD123, CD4 and CD56 to recognise BPDCN.
Common traps
- Treating early, symptom-free CLL: watching is the standard because early treatment does not prolong life.
- Confusing CML with a leukaemoid reaction: basophilia, a big spleen and no cause point to CML; BCR::ABL1 decides.
- Expecting high white counts in hairy cell leukaemia: it usually presents with pancytopenia.
- Forgetting autoimmune haemolysis in CLL: it can be the cause of a falling haemoglobin.
- Calling BPDCN a skin lymphoma or a chronic leukaemia: it is an aggressive blast neoplasm that often starts in the skin and is recognised by CD123 on CD4+ CD56+ blasts.
Test yourself
Think of the answer, then tap the question to see it.
Why is CML called a myeloproliferative neoplasm while CLL is classed with the lymphomas?
CML is a stem-cell disease that overproduces myeloid cells through BCR::ABL1; CLL is a clone of mature B lymphocytes, the same cell family as small lymphocytic lymphoma.
A 72-year-old has a high lymphocyte count, smudge cells and no symptoms. What confirms the diagnosis and what is usually done?
Flow cytometry showing clonal CD5+ CD23+ B cells confirms CLL; without symptoms or cytopenias the patient is usually monitored, not treated.
A patient with CLL develops a falling haemoglobin and jaundice. What should you test for?
Autoimmune haemolytic anaemia: DAT, reticulocytes, LDH, bilirubin and haptoglobin.
A 58-year-old with rheumatoid arthritis has repeated infections, severe neutropenia and many large granular lymphocytes. What is the likely diagnosis, and how is it confirmed?
T-cell LGL leukaemia; blood flow cytometry (CD3+ CD8+ CD57+) and a clonal T-cell receptor rearrangement confirm it, and a STAT3 mutation supports it.
Elsewhere in DurgiPedia
- Chronic myeloid leukaemia
- Chronic lymphocytic leukaemia (CLL/SLL)
- Hairy cell leukaemia: BRAF V600E, the dry tap and the red-pulp spleen
- Clonality testing: telling lymphoma from a reactive response
- T- and NK-cell leukaemias and extranodal lymphomas
Connections
In Pharmacology1
Educational content; it does not replace assessment by a doctor or your institution's protocols. It contains no doses.
Sources: Chronic myelogenous leukemia (CML) (MedlinePlus, US National Library of Medicine, 2024); Chronic lymphocytic leukemia (CLL) (MedlinePlus, US National Library of Medicine, 2024); Chronic Lymphocytic Leukemia Treatment (PDQ®)–Patient Version (National Cancer Institute (NCI), 2026); Hairy Cell Leukemia Treatment (PDQ®)–Patient Version (National Cancer Institute (NCI), 2026); Large Granular Lymphocytic Leukemia: Clinical Features, Molecular Pathogenesis, Diagnosis and Treatment (Cancers (Europe PMC), 2024); T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment (International Journal of Molecular Sciences (Europe PMC), 2023); Obituary for a diagnosis: B-cell prolymphocytic leukaemia (1974–2022) (HemaSphere (Europe PMC), 2024); Diagnostic approach to blastic plasmacytoid dendritic cell neoplasm: historical perspectives and current understanding (Journal of Clinical and Experimental Hematopathology (Europe PMC), 2025).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
